Vertex Pharmaceuticals and bluebird bio have entered into an agreement with CMS to participate in a new Medicaid payment ...

Vertex Pharmaceuticals Inc. and bluebird bio Inc. — are the first to take part in a new Medicaid model intended to expand ...

Bluebird bio (BLUE) and Vertex (VRTX) have entered into outcome-based agreements with CMS aimed at expanding patient access ...

The Centers for Medicare & Medicaid Services has successfully negotiated agreements with two drug manufacturers to ...

A recent study published in the journal Human Gene Therapy evaluated the long-term survival and cardiac efficacy of the gene ...

The Centers for Medicare & Medicaid Services Dec. 4 announced that drug manufacturers bluebird bio, inc. (manufacturer of ...

Gene Munster, Deepwater Asset Management managing partner, joins 'Squawk Box' to discuss Salesforce's Q3 results, the rise of ...

The Centers for Medicare & Medicaid Services said on Wednesday it had entered into agreements with Vertex Pharmaceuticals and ...

Gene therapies can be life-changing for people, but the high cost plus the burden of treatment remain barriers to access and ...

Researchers used mitochondrial gene editing to model genetic disorders in mice, revealing profound impacts on brain function, ...

One in 80 Ashkenazi Jews carry the TBCB gene; Israelis can now test for it as part of the Health Ministry national healthcare ...

CMS has reached agreements with bluebird bio and Vertex Pharmaceuticals for their FDA-approved gene therapies for sickle cell disease — Casgevy and Lyfgenia, respectively.